Volume 138, Issue 1 pp. 110-120
Cancer Genetics and Epigenetics

Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients

Giulia Partipilo

Giulia Partipilo

Functional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Search for more papers by this author
Giovanni Simone

Giovanni Simone

Pathology Department, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Search for more papers by this author
Anna Scattone

Anna Scattone

Pathology Department, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Search for more papers by this author
Emanuela Scarpi

Emanuela Scarpi

Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per Lo Studio E La Cura Dei Tumori (IRST)-IRCCS, Meldola, Italy

Search for more papers by this author
Amalia Azzariti

Amalia Azzariti

Clinical and Preclinical Pharmacology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Search for more papers by this author
Anita Mangia

Corresponding Author

Anita Mangia

Functional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Correspondence to: Anita Mangia, Functional Biomorphology Laboratory, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy, Fax: +39-0805555280, E-mail: [email protected]Search for more papers by this author
First published: 23 July 2015
Citations: 13

Conflict of interest: Nothing to report

Abstract

Understanding the expression of proteins involved in DNA damage response could improve knowledge of the pathways that contribute to familial and sporadic breast cancer (BC). We aimed to assess the different roles of BRCA1, poly(ADP-ribose) polymerase-1 (PARP1), BRCT-repeat inhibitor of hTERT expression (BRIT1) and novel SWItch 5 (SWI5) expression in 130 sporadic and 73 familial BC samples, by immunohistochemistry. In the sporadic group, negative nuclear BRCA1 (nBRCA1) expression was associated with positive PgR (p = 0.037). Negative association was found between nBRCA1 expression and HER2 (p = 0.001). In the familial group, nBRCA1 expression was associated with ER (p = 0.002). Reduced nBRCA1 expression was associated with higher histological grade and positive Ki67 both in sporadic (p = 0.0010, p = 0.047) and familial groups (p < 0.001, p = 0.001). Nuclear PARP1 (nPARP1) expression was associated with histological grade (p = 0.035) and positive PgR (p = 0.047) in sporadic cases. High cytoplasmic and low nuclear BRIT1 (cBRIT1 and nBRIT1) expression were associated with high histological grade in the familial group (p = 0.013, p = 0.025). Various statistical associations between the protein expressions were observed in the sporadic group, while in familial group only few associations were found. Univariate analyses showed that nPARP1 expression is able to discriminate between sporadic and familial tumors (OR 2.80, p = 0.002). Multivariate analyses proved that its overexpression is an independent factor associated with a high risk of sporadic tumor (OR 2.96, p = 0.017). Our findings indicate that nPARP1 expression is an independent factor for sporadic BCs and PARP1 inhibitors could be a promising therapy for different phenotypes.

Abstract

What's new?

Genetic mutations that alter mechanisms of DNA repair and genomic maintenance potentially heighten individual susceptibility to cancer. In the present study, this relationship was examined in the context of familial and sporadic breast cancer. Nuclear expression of PARP1, a protein involved in DNA repair, was found to serve as an independent factor for sporadic breast cancer. Meanwhile, nBRCA1 expression was associated with aggressive tumor phenotypes, with potentially important roles in the pathogenesis of both familial and sporadic malignancy. The findings highlight the complexities of aberrant DNA repair in breast cancer and the therapeutic potential of PARP1 inhibition.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.